A	O
novel	O
rapid	O
analysis	B:C0936012
using	O
mass	O
spectrometry	I:C0037813
to	O
evaluate	O
downstream	O
refolding	O
of	O
recombinant	O
human	I:C0904505
insulin	I:C0904505
-	I:C0904505
like	I:C0904505
growth	I:C0904505
factor	I:C0904505
-	I:C0904505
1	I:C0904505
(	O
mecasermin	O
)	O
.	O

A	O
novel	O
rapid	O
analysis	O
using	O
mass	B:C0037813
spectrometry	I:C0037813
to	O
evaluate	O
downstream	O
refolding	O
of	O
recombinant	O
human	I:C0904505
insulin	I:C0904505
-	I:C0904505
like	I:C0904505
growth	I:C0904505
factor	I:C0904505
-	I:C0904505
1	I:C0904505
(	O
mecasermin	O
)	O
.	O

A	O
novel	O
rapid	O
analysis	O
using	O
mass	O
spectrometry	I:C0037813
to	O
evaluate	O
downstream	B:C0522506
refolding	O
of	O
recombinant	O
human	I:C0904505
insulin	I:C0904505
-	I:C0904505
like	I:C0904505
growth	I:C0904505
factor	I:C0904505
-	I:C0904505
1	I:C0904505
(	O
mecasermin	O
)	O
.	O

A	O
novel	O
rapid	O
analysis	O
using	O
mass	O
spectrometry	I:C0037813
to	O
evaluate	O
downstream	O
refolding	B:C0162847
of	O
recombinant	O
human	I:C0904505
insulin	I:C0904505
-	I:C0904505
like	I:C0904505
growth	I:C0904505
factor	I:C0904505
-	I:C0904505
1	I:C0904505
(	O
mecasermin	O
)	O
.	O

A	O
novel	O
rapid	O
analysis	O
using	O
mass	O
spectrometry	I:C0037813
to	O
evaluate	O
downstream	O
refolding	O
of	O
recombinant	B:C0904505
human	I:C0904505
insulin	I:C0904505
-	I:C0904505
like	I:C0904505
growth	I:C0904505
factor	I:C0904505
-	I:C0904505
1	I:C0904505
(	O
mecasermin	O
)	O
.	O

A	O
novel	O
rapid	O
analysis	O
using	O
mass	O
spectrometry	I:C0037813
to	O
evaluate	O
downstream	O
refolding	O
of	O
recombinant	O
human	I:C0904505
insulin	I:C0904505
-	I:C0904505
like	I:C0904505
growth	I:C0904505
factor	I:C0904505
-	I:C0904505
1	I:C0904505
(	O
mecasermin	B:C0904505
)	O
.	O

Mecasermin	B:C0904505
is	O
used	O
to	O
treat	O
elevated	O
blood	I:C0020456
sugar	I:C0020456
as	O
well	O
as	O
growth	O
hormone	I:C0037663
-	O
resistant	O
Laron	O
-	I:C0271568
type	I:C0271568
dwarfism	I:C0271568
.	O

Mecasermin	O
is	O
used	O
to	O
treat	O
elevated	B:C0020456
blood	I:C0020456
sugar	I:C0020456
as	O
well	O
as	O
growth	O
hormone	I:C0037663
-	O
resistant	O
Laron	O
-	I:C0271568
type	I:C0271568
dwarfism	I:C0271568
.	O

Mecasermin	O
is	O
used	O
to	O
treat	O
elevated	O
blood	I:C0020456
sugar	I:C0020456
as	O
well	O
as	O
growth	B:C0037663
hormone	I:C0037663
-	O
resistant	O
Laron	O
-	I:C0271568
type	I:C0271568
dwarfism	I:C0271568
.	O

Mecasermin	O
is	O
used	O
to	O
treat	O
elevated	O
blood	I:C0020456
sugar	I:C0020456
as	O
well	O
as	O
growth	O
hormone	I:C0037663
-	O
resistant	O
Laron	B:C0271568
-	I:C0271568
type	I:C0271568
dwarfism	I:C0271568
.	O

Mecasermin	B:C0904505
isolated	O
from	O
inclusion	O
bodies	I:C0007637
in	O
extracts	O
of	O
E.coli	O
must	O
be	O
refolded	O
to	O
acquire	O
sufficient	O
activity	O
.	O

Mecasermin	O
isolated	O
from	O
inclusion	B:C0007637
bodies	I:C0007637
in	O
extracts	O
of	O
E.coli	O
must	O
be	O
refolded	O
to	O
acquire	O
sufficient	O
activity	O
.	O

Mecasermin	O
isolated	O
from	O
inclusion	O
bodies	I:C0007637
in	O
extracts	O
of	O
E.coli	B:C0014834
must	O
be	O
refolded	O
to	O
acquire	O
sufficient	O
activity	O
.	O

However	O
,	O
there	O
is	O
no	O
rapid	O
analytical	O
method	O
for	O
monitoring	O
refolding	B:C0162847
during	O
the	O
purification	O
process	O
.	O

However	O
,	O
there	O
is	O
no	O
rapid	O
analytical	O
method	O
for	O
monitoring	O
refolding	O
during	O
the	O
purification	B:C0597301
process	O
.	O

We	O
prepared	O
mecasermin	B:C0904505
drug	O
product	I:C0013227
,	O
in	O
-	O
process	O
samples	O
during	O
the	O
oxidation	O
of	O
mecasermin	O
,	O
forced	O
-	O
reduced	O
mecasermin	O
,	O
and	O
aerially	O
oxidized	O
mecasermin	O
after	O
forced	O
reduction	O
.	O

We	O
prepared	O
mecasermin	O
drug	B:C0013227
product	I:C0013227
,	O
in	O
-	O
process	O
samples	O
during	O
the	O
oxidation	O
of	O
mecasermin	O
,	O
forced	O
-	O
reduced	O
mecasermin	O
,	O
and	O
aerially	O
oxidized	O
mecasermin	O
after	O
forced	O
reduction	O
.	O

We	O
prepared	O
mecasermin	O
drug	O
product	I:C0013227
,	O
in	O
-	O
process	O
samples	O
during	O
the	O
oxidation	B:C0030011
of	O
mecasermin	O
,	O
forced	O
-	O
reduced	O
mecasermin	O
,	O
and	O
aerially	O
oxidized	O
mecasermin	O
after	O
forced	O
reduction	O
.	O

We	O
prepared	O
mecasermin	O
drug	O
product	I:C0013227
,	O
in	O
-	O
process	O
samples	O
during	O
the	O
oxidation	O
of	O
mecasermin	B:C0904505
,	O
forced	O
-	O
reduced	O
mecasermin	O
,	O
and	O
aerially	O
oxidized	O
mecasermin	O
after	O
forced	O
reduction	O
.	O

We	O
prepared	O
mecasermin	O
drug	O
product	I:C0013227
,	O
in	O
-	O
process	O
samples	O
during	O
the	O
oxidation	O
of	O
mecasermin	O
,	O
forced	O
-	O
reduced	O
mecasermin	B:C0904505
,	O
and	O
aerially	O
oxidized	O
mecasermin	O
after	O
forced	O
reduction	O
.	O

We	O
prepared	O
mecasermin	O
drug	O
product	I:C0013227
,	O
in	O
-	O
process	O
samples	O
during	O
the	O
oxidation	O
of	O
mecasermin	O
,	O
forced	O
-	O
reduced	O
mecasermin	O
,	O
and	O
aerially	O
oxidized	O
mecasermin	B:C0904505
after	O
forced	O
reduction	O
.	O

Desalted	O
mecasermin	B:C0904505
samples	O
were	O
analyzed	O
using	O
MALDI	O
-	I:C0282597
ISD	I:C0282597
.	O

Desalted	O
mecasermin	O
samples	O
were	O
analyzed	O
using	O
MALDI	B:C0282597
-	I:C0282597
ISD	I:C0282597
.	O

The	O
charge	O
state	O
distribution	O
(	O
CSD	O
)	O
of	O
mecasermin	B:C0904505
ions	O
was	O
evaluated	O
using	O
ESI	O
-	I:C0596495
MS	I:C0596495
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	O
.	O

The	O
charge	O
state	O
distribution	O
(	O
CSD	O
)	O
of	O
mecasermin	O
ions	O
was	O
evaluated	O
using	O
ESI	B:C0596495
-	I:C0596495
MS	I:C0596495
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	O
.	O

The	O
charge	O
state	O
distribution	O
(	O
CSD	O
)	O
of	O
mecasermin	O
ions	O
was	O
evaluated	O
using	O
ESI	O
-	I:C0596495
MS	I:C0596495
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	B:C0008562
.	O

The	O
drift	O
time	O
and	O
collision	O
cross-sectional	O
areas	O
(	O
CCS	O
)	O
of	O
mecasermin	B:C0904505
ions	O
were	O
evaluated	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	O
.	O

The	O
drift	O
time	O
and	O
collision	O
cross-sectional	O
areas	O
(	O
CCS	O
)	O
of	O
mecasermin	O
ions	O
were	O
evaluated	O
using	O
ESI	B:C0022885
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	O
.	O

The	O
drift	O
time	O
and	O
collision	O
cross-sectional	O
areas	O
(	O
CCS	O
)	O
of	O
mecasermin	O
ions	O
were	O
evaluated	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	B:C0008562
.	O

MALDI	B:C0282597
-ISD	I:C0282597
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI	O
-	I:C0596495
MS	I:C0596495
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
revealed	O
the	O
relationship	O
between	O
the	O
folded	O
and	O
unfolded	O
proteoforms	O
of	O
forced	O
-	O
reduced	O
mecasermin	O
and	O
aerially	O
oxidized	O
mecasermin	O
with	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
drug	O
product	I:C0013227
.	O

MALDI	O
-ISD	I:C0282597
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI	B:C0596495
-	I:C0596495
MS	I:C0596495
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
revealed	O
the	O
relationship	O
between	O
the	O
folded	O
and	O
unfolded	O
proteoforms	O
of	O
forced	O
-	O
reduced	O
mecasermin	O
and	O
aerially	O
oxidized	O
mecasermin	O
with	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
drug	O
product	I:C0013227
.	O

MALDI	O
-ISD	I:C0282597
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI	O
-	I:C0596495
MS	I:C0596495
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI	B:C0022885
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
revealed	O
the	O
relationship	O
between	O
the	O
folded	O
and	O
unfolded	O
proteoforms	O
of	O
forced	O
-	O
reduced	O
mecasermin	O
and	O
aerially	O
oxidized	O
mecasermin	O
with	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
drug	O
product	I:C0013227
.	O

MALDI	O
-ISD	I:C0282597
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI	O
-	I:C0596495
MS	I:C0596495
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
revealed	O
the	O
relationship	O
between	O
the	O
folded	B:C0332462
and	O
unfolded	O
proteoforms	O
of	O
forced	O
-	O
reduced	O
mecasermin	O
and	O
aerially	O
oxidized	O
mecasermin	O
with	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
drug	O
product	I:C0013227
.	O

MALDI	O
-ISD	I:C0282597
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI	O
-	I:C0596495
MS	I:C0596495
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
revealed	O
the	O
relationship	O
between	O
the	O
folded	O
and	O
unfolded	O
proteoforms	B:C1510464
of	O
forced	O
-	O
reduced	O
mecasermin	O
and	O
aerially	O
oxidized	O
mecasermin	O
with	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
drug	O
product	I:C0013227
.	O

MALDI	O
-ISD	I:C0282597
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI	O
-	I:C0596495
MS	I:C0596495
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
revealed	O
the	O
relationship	O
between	O
the	O
folded	O
and	O
unfolded	O
proteoforms	O
of	O
forced	O
-	O
reduced	O
mecasermin	B:C0904505
and	O
aerially	O
oxidized	O
mecasermin	O
with	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
drug	O
product	I:C0013227
.	O

MALDI	O
-ISD	I:C0282597
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI	O
-	I:C0596495
MS	I:C0596495
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
revealed	O
the	O
relationship	O
between	O
the	O
folded	O
and	O
unfolded	O
proteoforms	O
of	O
forced	O
-	O
reduced	O
mecasermin	O
and	O
aerially	O
oxidized	O
mecasermin	B:C0904505
with	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
drug	O
product	I:C0013227
.	O

MALDI	O
-ISD	I:C0282597
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI	O
-	I:C0596495
MS	I:C0596495
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
revealed	O
the	O
relationship	O
between	O
the	O
folded	O
and	O
unfolded	O
proteoforms	O
of	O
forced	O
-	O
reduced	O
mecasermin	O
and	O
aerially	O
oxidized	O
mecasermin	O
with	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	B:C0904505
drug	O
product	I:C0013227
.	O

MALDI	O
-ISD	I:C0282597
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI	O
-	I:C0596495
MS	I:C0596495
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
revealed	O
the	O
relationship	O
between	O
the	O
folded	O
and	O
unfolded	O
proteoforms	O
of	O
forced	O
-	O
reduced	O
mecasermin	O
and	O
aerially	O
oxidized	O
mecasermin	O
with	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
drug	B:C0013227
product	I:C0013227
.	O

The	O
collision	O
cross-sectional	O
area	O
,	O
which	O
is	O
determined	O
using	O
ESI	B:C0022885
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
,	O
provided	O
proteoform	O
information	O
through	O
rapid	O
monitoring	O
(	O
<	O
2	O
min	O
)	O
of	O
in	O
-	O
process	O
samples	O
during	O
the	O
manufacture	O
of	O
mecasermin	O
.	O

The	O
collision	O
cross-sectional	O
area	O
,	O
which	O
is	O
determined	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
,	O
provided	O
proteoform	B:C1510464
information	O
through	O
rapid	O
monitoring	O
(	O
<	O
2	O
min	O
)	O
of	O
in	O
-	O
process	O
samples	O
during	O
the	O
manufacture	O
of	O
mecasermin	O
.	O

The	O
collision	O
cross-sectional	O
area	O
,	O
which	O
is	O
determined	O
using	O
ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
,	O
provided	O
proteoform	O
information	O
through	O
rapid	O
monitoring	O
(	O
<	O
2	O
min	O
)	O
of	O
in	O
-	O
process	O
samples	O
during	O
the	O
manufacture	O
of	O
mecasermin	B:C0904505
.	O

ESI	B:C0022885
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	O
is	O
a	O
rapid	O
and	O
robust	O
method	O
for	O
analyzing	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	O
changes	O
during	O
the	O
oxidation	O
of	O
mecasermin	O
.	O

ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	B:C0008562
is	O
a	O
rapid	O
and	O
robust	O
method	O
for	O
analyzing	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	O
changes	O
during	O
the	O
oxidation	O
of	O
mecasermin	O
.	O

ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	O
is	O
a	O
rapid	O
and	O
robust	O
method	O
for	O
analyzing	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	B:C0904505
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	O
changes	O
during	O
the	O
oxidation	O
of	O
mecasermin	O
.	O

ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	O
is	O
a	O
rapid	O
and	O
robust	O
method	O
for	O
analyzing	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	B:C1510464
changes	O
during	O
the	O
oxidation	O
of	O
mecasermin	O
.	O

ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	O
is	O
a	O
rapid	O
and	O
robust	O
method	O
for	O
analyzing	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	O
changes	O
during	O
the	O
oxidation	B:C0030011
of	O
mecasermin	O
.	O

ESI	O
-	I:C0022885
IMS	I:C0022885
-	I:C0022885
MS	I:C0022885
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	O
is	O
a	O
rapid	O
and	O
robust	O
method	O
for	O
analyzing	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	O
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	O
changes	O
during	O
the	O
oxidation	O
of	O
mecasermin	B:C0904505
.	O

ESI	B:C0022885
-	I:C0022885
IMS	I:C0022885
-MS	I:C0022885
is	O
applicable	O
as	O
a	O
process	O
analytical	O
technology	O
tool	O
for	O
identifying	O
the	O
"	O
critical	O
quality	O
attributes	O
"	O
and	O
implementing	O
"	O
quality	O
by	O
design	O
"	O
for	O
manufacturing	O
mecasermin	O
.	O

ESI	O
-	I:C0022885
IMS	I:C0022885
-MS	I:C0022885
is	O
applicable	O
as	O
a	O
process	O
analytical	O
technology	O
tool	O
for	O
identifying	O
the	O
"	O
critical	O
quality	O
attributes	O
"	O
and	O
implementing	O
"	O
quality	O
by	O
design	O
"	O
for	O
manufacturing	O
mecasermin	B:C0904505
.	O

